☰

Matthew W. VanBrocklin, Ph.D. - Publications

Affiliations: 
2007 Western Michigan University, Kalamazoo, MI, United States 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Parkman GL, Turapov T, Kircher DA, Burnett WJ, Stehn CM, O'Toole K, Culver KM, Chadwick AT, Elmer RC, Flaherty R, Stanley KA, Foth M, Lum DH, Judson-Torres RL, Friend JE, ... VanBrocklin MW, et al. Genetic silencing of AKT induces melanoma cell death via mTOR suppression. Molecular Cancer Therapeutics. PMID 37931033 DOI: 10.1158/1535-7163.MCT-23-0474  0.332
2020 Grigore F, Yang H, Hanson ND, VanBrocklin MW, Sarver AL, Robinson JP. BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases. Neoplasia (New York, N.Y.). 22: 376-389. PMID 32629178 DOI: 10.1016/J.Neo.2020.06.006  0.456
2020 Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, Holmen SL. Abstract 2736: AKT1E17Kactivates focal adhesion kinase and promotes melanoma brain metastasis Tumor Biology. DOI: 10.1158/1538-7445.Am2020-2736  0.318
2019 Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, et al. AKT1E17K activates focal adhesion kinase and promotes melanoma brain metastasis. Molecular Cancer Research : McR. PMID 31138602 DOI: 10.1158/1541-7786.Mcr-18-1372  0.458
2018 Grossman D, Kumar D, Rahman H, Tyagi E, Liu T, Li C, Lu R, Lum D, Holmen SL, Maschek JA, Cox JE, VanBrocklin MW. Aspirin suppresses PGE and activates AMP kinase to inhibit melanoma cell motility, pigmentation and selective tumor growth . Cancer Prevention Research (Philadelphia, Pa.). PMID 30021726 DOI: 10.1158/1940-6207.Capr-18-0087  0.467
2018 Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL. Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Reports. 23: 1553-1564. PMID 29719265 DOI: 10.1016/J.Celrep.2018.03.133  0.41
2018 Yu D, Boekholder R, VanBrocklin M, Sonnen J, Colman H, Holmen S. Tmod-19. Mutant Idh1 Promotes Glioma Formation In Vivo Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.1131  0.326
2017 Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW. Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Research. 27: 545-557. PMID 29076949 DOI: 10.1097/Cmr.0000000000000403  0.469
2017 Shin CH, Robinson JP, Sonnen JA, Welker AE, Yu DX, VanBrocklin MW, Holmen SL. HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss. Oncogene. PMID 28368403 DOI: 10.1038/Onc.2017.83  0.421
2017 Yang H, Kircher DA, Kim KH, Grossmann AH, VanBrocklin MW, Holmen SL, Robinson JP. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Oncogene. PMID 28263969 DOI: 10.1038/Onc.2016.526  0.486
2017 Philip B, Silvis M, Yu D, Shin C, Robinson J, Sonnen J, Welker A, VanBrocklin M, Colman H, Holmen S. Tmod-45. Defining The Role Of Mutant Idh In Glioma Initiation Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.1081  0.308
2016 Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget. PMID 27391442 DOI: 10.18632/Oncotarget.10453  0.327
2016 Kircher D, Cho J, Robinson J, Arave R, Green R, Chen G, Davies M, Grossmann A, VanBrocklin M, McMahon M, Holmen S. Abstract 37: AKT1 activation promotes brain metastasis in a mouse model of melanoma Clinical Cancer Research. 22: 37-37. DOI: 10.1158/1557-3265.Pmsclingen15-37  0.405
2015 Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL. AKT1 Activation Promotes Development of Melanoma Metastases. Cell Reports. 13: 898-905. PMID 26565903 DOI: 10.1016/J.Celrep.2015.09.057  0.431
2015 Bowen RC, Meek S, Williams M, Grossmann KF, Andtbacka RHI, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Holmen SL, VanBrocklin MW, Khong HT. A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma. Journal of Clinical Oncology. 33: 3018-3018. DOI: 10.1200/Jco.2015.33.15_Suppl.3018  0.308
2015 Robinson J, Rebecca V, Chen G, Davies M, VanBrocklin M, Holmen S. Abstract B26: Receptor tyrosine kinase signaling mediates resistance in NRAS mutant melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-B26  0.511
2014 Ifediba M, Burnett D, Hovda N, Burnett W, VanBrocklin M. Abstract B53: Utilizing bimolecular fluorescent complementation to identify inhibitors of RAL and KRAS Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B53  0.315
2014 Ifediba M, Burnett D, Hovda N, Burnett W, VanBrocklin M. Abstract 3732: Utilizing Bimolecular Fluorescent Complementation to Identify Inhibitors of RAL and KRAS Cancer Research. 74: 3732-3732. DOI: 10.1158/1538-7445.Am2014-3732  0.31
2014 Robinson GL, Guthrie MR, Ifediba M, VanBrocklin MW, Holmen SL. Abstract 2438: Defining the role of mutant isocitrate dehydrogenase in malignant glioma Cancer Research. 74: 2438-2438. DOI: 10.1158/1538-7445.Am2014-2438  0.346
2013 Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, Vanbrocklin MW. Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss. Genes & Cancer. 4: 476-85. PMID 24386508 DOI: 10.1177/1947601913513268  0.437
2012 Vanbrocklin MW, Robinson JP, Lastwika KJ, McKinney AJ, Gach HM, Holmen SL. Ink4a/Arf loss promotes tumor recurrence following Ras inhibition. Neuro-Oncology. 14: 34-42. PMID 22015595 DOI: 10.1093/Neuonc/Nor184  0.432
2012 Robinson JP, VanBrocklin MW, Holmen SL. Abstract 2365: Defining the role of Akt activation in melanoma development and progression Cancer Research. 72: 2365-2365. DOI: 10.1158/1538-7445.Am2012-2365  0.473
2012 Robinson JP, Holmen SL, VanBrocklin M. Abstract A41: Developing a mouse model of melanoma to identify drug resistance mechanisms Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-A41  0.452
2011 Robinson JP, Vanbrocklin MW, McKinney AJ, Gach HM, Holmen SL. Akt signaling is required for glioblastoma maintenance in vivo. American Journal of Cancer Research. 1: 155-167. PMID 21796274  0.373
2011 Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Oncogene. 30: 1341-50. PMID 21057530 DOI: 10.1038/Onc.2010.513  0.44
2011 VanBrocklin MW, Robinson JP, McKinney AJ, Holmen SL. Abstract 2860: Defining the role of NRAS in melanoma maintenance using a novel inducible mouse model Cancer Research. 71: 2860-2860. DOI: 10.1158/1538-7445.Am2011-2860  0.468
2010 VanBrocklin MW, Robinson JP, Lastwika KJ, Khoury JD, Holmen SL. Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice. Pigment Cell & Melanoma Research. 23: 531-41. PMID 20444198 DOI: 10.1111/J.1755-148X.2010.00717.X  0.396
2010 Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL. Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene. 29: 335-44. PMID 19855433 DOI: 10.1038/Onc.2009.333  0.446
2009 Vanbrocklin MW, Robinson JP, Whitwam T, Guilbeault AR, Koeman J, Swiatek PJ, Vande Woude GF, Khoury JD, Holmen SL. Met amplification and tumor progression in Cdkn2a-deficient melanocytes. Pigment Cell & Melanoma Research. 22: 454-60. PMID 19422607 DOI: 10.1111/J.1755-148X.2009.00576.X  0.465
2009 VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL. Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Research. 69: 1985-94. PMID 19244105 DOI: 10.1158/0008-5472.Can-08-3934  0.434
2003 Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Research. 63: 8330-7. PMID 14678993  0.318
2002 Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Vande Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proceedings of the National Academy of Sciences of the United States of America. 99: 3052-7. PMID 11867750 DOI: 10.1073/Pnas.052707699  0.425
2000 VanBrocklin M, Federspiel MJ. Capsid-targeted viral inactivation can eliminate the production of infectious murine leukemia virus in vitro Virology. 267: 111-123. PMID 10648188 DOI: 10.1006/Viro.1999.0113  0.326
2000 Wilson CA, Wong S, VanBrocklin M, Federspiel MJ. Extended analysis of the in vitro tropism of porcine endogenous retrovirus. Journal of Virology. 74: 49-56. PMID 10590090 DOI: 10.1128/Jvi.74.1.49-56.2000  0.311
1998 Schaefer-Klein J, Givol I, Barsov EV, Whitcomb JM, VanBrocklin M, Foster DN, Federspiel MJ, Hughes SH. The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virology. 248: 305-311. PMID 9721239 DOI: 10.1006/Viro.1998.9291  0.304
Show low-probability matches.